Cadrenal Therapeutics (Cadrenal Therapeutics) Dividends per Share : $0.00 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Dividends per Share?

Cadrenal Therapeutics's dividends per share for the three months ended in Mar. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Cadrenal Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Cadrenal Therapeutics Dividends per Share Historical Data

The historical data trend for Cadrenal Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Dividends per Share Chart

Cadrenal Therapeutics Annual Data

Trend

Dec22

Dec23

Dividends per Share

Cadrenal Therapeutics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividends per Share	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Cadrenal Therapeutics's Dividends per Share

For the Biotechnology subindustry, Cadrenal Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadrenal Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Cadrenal Therapeutics's Dividend Yield % falls into.

Cadrenal Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

Cadrenal Therapeutics (NAS:CVKD) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Cadrenal Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.1
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Cadrenal Therapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082

Website

https://www.cadrenal.com

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Executives

John Raymond Murphy	director	233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham	director, 10 percent owner, officer: CEO and Chairman	89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo	officer: Chief Medical Officer	13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot	officer: Chief Financial Officer	802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson	director	2483 NE JULEP STREET, ISSAQUAH WA 98029